Scientific publications

The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma

Feb 22, 2022 | Magazine: Revista Española de Medicina Nuclear e Imagen Molecular

M Rodríguez-Fraile  1 , P Tamayo Alonso  2 , J J Rosales  3 , María de Arcocha-Torres  4 , A P Caresia-Aróztegui  5 , María Puig Cózar-Santiago  6 , Javier Orcajo-Rincon  7 , Marc Simó Perdigó  8 , R C Delgado Bolton  9 , C Artigas Guix  10 , Oncology Working Group of the Spanish Society of Nuclear Medicine and Molecular Imaging


Prostate cancer (PC) is the most common tumor in men in the West and the fifth leading cause of cancer-related death. The use of PSMA radioligands has represented an important advance both in its diagnosis, through PET molecular imaging, and in its treatment in advanced stages of the disease.

This article reviews the contribution of PET studies with PSMA radioligands in initial staging, in tumor detection in biochemical recurrence (elevation of PSA) after treatment with curative intent, and in the more advanced stages of the disease (castration resistant PC or CRPC).

The contribution of PSMA radioligand therapy (PSMA-RLT) in CRPC patients who progress to standard therapy is also analyzed.

CITATION  Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Feb 22;S2253-8089(22)00003-9. doi: 10.1016/j.remnie.2022.02.001